Clinical trials vs real life
Dr Filip Baert (Roeselare, Belgium) gives a summary of his session on trial endpoints vs therapeutic objectives. he also discusses the role of ECCO in improving the data generated in… read more.
Dr Filip Baert (Roeselare, Belgium) gives a summary of his session on trial endpoints vs therapeutic objectives. he also discusses the role of ECCO in improving the data generated in… read more.
Predicting disease years before diagnosis is a passion for Professor Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, NY, USA). Here he discusses 2 studies presented at… read more.
In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.
In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.
The future is now – importance of the IBD nurse in patient care. by Maria Dalby Marian O’Connor (St Mark’s Hospital, London, UK ), Silvio Danese (Milan, Italy)… read more.
Silvio Danese, Humanitas Clinical and Research Hospital, Milan, Italy. Article by Maria Dalby – The current paradigm for managing inflammatory conditions is to suppress the inflammatory response by… read more.
New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.
Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.